News

Genoskin appoints Eric Merle as first chief commercial officer Salem, MA. – January 4, 2019 – Genoskin, an innovative provider of ex vivo clinical testing skin models and solutions, announced today the addition of Eric Merle as the company’s first chief commercial officer. The new position will see him take responsibility for all regions in which Genoskin operates. Eric has

Thank you so much for making this past year outstanding! We look forward to further our partnerships and helping you develop more relevant data for 2019! Best wishes of success. The Genoskin team. To keep up-to-date with Genoskin’s latest news, follow us on Twitter and LinkedIn or subscribe to our newsletter. You can also contact us to learn more about our activities and services.

NativeSkin kit now available for lab delivery on Mondays! We have great news! We have been working hard to optimize our technology and processes this year. We are now able to offer a solution to those seeking to work on our NativeSkin kits throughout the work week. If you order NativeSkin kit, we will prepare and ship them in time for you to receive them on Mondays. Our proprietary

Genoskin signs distribution agreement with Japan's Fujifilm Wako Pure Chemical The Genoskin team is excited to announce that we've signed an agreement with the Japanese Fujifilm Wako Pure Chemical Corporation to distribute Genoskin's ex vivo human skin models to customers in Japan. This agreement will enable Genoskin to respond to the specific needs of exisiting and potential customers in Japan and to increase its

Posts navigation

Genoskin develops and markets innovative testing tools to study the effects of pharmaceutical, cosmetic and chemical products on human skin. Our skin models are an alternative to animal testing and contain donated human skin that is kept alive for up to 7 days for repeated application and predictive results.